Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 14 min ago
Peer-reviewedCC BY 4.0JACC: Advances

Hypertension and Subclinical Vascular Damage After Allogeneic Hematopoietic Stem Cell Transplantation

  • Wejdan Bin Obaid, MD1
  • Mar Bellido, MD, PhD1
  • Arie M. van Roon, PhD2
  • Anouschka Biswana, MSc, MBA1
  • Fleurine Meppelink, MSc1
  • Michaël V. Lukens, PhD3
  • Hilde Kooistra, MD, PhD1
  • Goda Choi, MD, PhD1
  • Linde Morsink, MD, PhD1
  • Carin Hazenberg, MD1
  • Gerwin Huls, MD, PhD1
  • Joop D. Lefrandt, MD, PhD2
  1. 1Department of Hematology, University Medical Centre Groningen, University of Groningen, Groningen, the Netherlands; University of Groningen, Groningen, the Netherlands
  2. 2University of Groningen, Groningen, the Netherlands; Division of Vascular Medicine, Department of Internal Medicine, University Medical Centre Groningen, Groningen, the Netherlands
  3. 3University of Groningen, Groningen, the Netherlands; Department of Laboratory Medicine, University Medical Centre Groningen, Groningen, the Netherlands
Read full textDOICite

Abstract

Background: Patients with hematological malignancies undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT) face a higher risk of premature cardiovascular disease that may partly be explained by hypertension. Objectives: The authors studied the prevalence of hypertension in alloHSCT survivors at least 1 year post-transplant. Methods: Two hundred survivors were clinically screened for hypertension. Hypertension was defined according to established ambulatory blood pressure monitoring (ABPM) thresholds. Subclinical vascular damage was assessed through carotid intima-media thickness by ultrasonography of the carotid arteries, pulse wave velocity, and renal function. Results: Of the 200 patients, 168 (84%) completed the 24-hour ABPM. The median age was 57 years (IQR: 46.3-65.0; range: 18-75). Of the 168 patients, 90 patients (53.6%) had hypertension, of which 26 (15.5%) were newly diagnosed, and 56 (33.3%) were untreated. Hypertensive patients by ABPM tended to be older (median 58 [IQR: 49-67] vs 55.5 [IQR: 39.75-64] years; P = 0.060), had a higher intima-media thickness (0.84 ± 0.25 vs 0.76 ± 0.26 mm; P = 0.009), higher pulse wave velocity values (9.0 ± 2.3 vs 7.3 ± 1.6 m/s; P < 0.001), and lower mean estimated glomerular filtration rate (72.3 ± 18.7 vs 80.4 ± 22.5 mL/min/1.73 m 2 ; P = 0.010) compared to normotensive patients. In the logistic regression model, both age in years (OR: 1.03; 95% CI: 1.01-1.05; P = 0.019) and family history of cardiovascular disease and/or premature death (OR: 2.28; 95% CI: 1.17-4.44; P = 0.016) were independently associated with hypertension. Conclusions: Hypertension is highly prevalent, underrecognized, and undertreated in alloHSCT survivors and is cross-sectionally associated with subclinical vascular and renal organ damage.

Related

  1. The role of allogeneic hematopoietic stem cell transplantation in adults with mature T‐cell lymphomas
    Laura Diana Stocker, Lisa Thielecke, Constantin Schmitz +3
    The Cochrane Database of Systematic ReviewsPeer-reviewedPublisher termsFull textGeneral medicinePMC
  2. Case Report: SAPHO syndrome mimicking osseous relapse after haploidentical allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia
    Wenhui Zhang, Xiaolin Ma, Xianglan Liu +6
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Viral Respiratory Infections Diagnosed by Multiplex PCR after Allogeneic Hematopoietic Stem Cell Transplantation: Long-Term Incidence and Outcome
    Alice Wolfromm, Raphael Porcher, Jérome Legoff +7
    Biology of Blood and Marrow TransplantationPeer-reviewedCC BY-NC-NDFull text40 citedEpidemiology & public healthHAL
  4. Secondary Pulmonary Alveolar Proteinosis after Allogeneic Hematopoietic Stem Cell Transplantation in the Setting of an Respiratory Syncytial Virus Infection: A Case Report
    Yuki Mori, Koichi Nakase, Risa Hashida +2
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
  5. TP53-mutated Therapy-related Leukemia with the Der(5;17)(p10;q10) Chromosomal Abnormality Following Chemotherapy for Acute Promyelocytic Leukemia Bridged to Allogeneic Hematopoietic Stem Cell Transplantation Using CPX-351
    Aya Kamiya, Yoshinori Hashimoto, Hiromi Omura +1
    Internal MedicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE

Cite

BibTeXRIS
BibTeX
@article{wejdanbinobaid2026hypertension,
  title = {{Hypertension and Subclinical Vascular Damage After Allogeneic Hematopoietic Stem Cell Transplantation}},
  author = {Wejdan Bin Obaid, MD and Mar Bellido, MD, PhD and Arie M. van Roon, PhD and Anouschka Biswana, MSc, MBA and Fleurine Meppelink, MSc and Michaël V. Lukens, PhD and Hilde Kooistra, MD, PhD and Goda Choi, MD, PhD and Linde Morsink, MD, PhD and Carin Hazenberg, MD and Gerwin Huls, MD, PhD and Joop D. Lefrandt, MD, PhD},
  journal = {JACC: Advances},
  year = {2026},
  month = sep,
  doi = {10.1016/j.jacadv.2026.103314},
  url = {https://doi.org/10.1016/j.jacadv.2026.103314},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Hypertension and Subclinical Vascular Damage After Allogeneic Hematopoietic Stem Cell Transplantation
AU  - Wejdan Bin Obaid, MD
AU  - Mar Bellido, MD, PhD
AU  - Arie M. van Roon, PhD
AU  - Anouschka Biswana, MSc, MBA
AU  - Fleurine Meppelink, MSc
AU  - Michaël V. Lukens, PhD
AU  - Hilde Kooistra, MD, PhD
AU  - Goda Choi, MD, PhD
AU  - Linde Morsink, MD, PhD
AU  - Carin Hazenberg, MD
AU  - Gerwin Huls, MD, PhD
AU  - Joop D. Lefrandt, MD, PhD
PY  - 2026
DA  - 2026/09/22
JO  - JACC: Advances
DO  - 10.1016/j.jacadv.2026.103314
UR  - https://doi.org/10.1016/j.jacadv.2026.103314
AB  - Background: Patients with hematological malignancies undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT) face a higher risk of premature cardiovascular disease that may partly be explained by hypertension. Objectives: The authors studied the prevalence of hypertension in alloHSCT survivors at least 1 year post-transplant. Methods: Two hundred survivors were clinically screened for hypertension. Hypertension was defined according to established ambulatory blood pressure monitoring (ABPM) thresholds. Subclinical vascular damage was assessed through carotid intima-media thickness by ultrasonography of the carotid arteries, pulse wave velocity, and renal function. Results: Of the 200 patients, 168 (84%) completed the 24-hour ABPM. The median age was 57 years (IQR: 46.3-65.0; range: 18-75). Of the 168 patients, 90 patients (53.6%) had hypertension, of which 26 (15.5%) were newly diagnosed, and 56 (33.3%) were untreated. Hypertensive patients by ABPM tended to be older (median 58 [IQR: 49-67] vs 55.5 [IQR: 39.75-64] years; P = 0.060), had a higher intima-media thickness (0.84 ± 0.25 vs 0.76 ± 0.26 mm; P = 0.009), higher pulse wave velocity values (9.0 ± 2.3 vs 7.3 ± 1.6 m/s; P < 0.001), and lower mean estimated glomerular filtration rate (72.3 ± 18.7 vs 80.4 ± 22.5 mL/min/1.73 m 2 ; P = 0.010) compared to normotensive patients. In the logistic regression model, both age in years (OR: 1.03; 95% CI: 1.01-1.05; P = 0.019) and family history of cardiovascular disease and/or premature death (OR: 2.28; 95% CI: 1.17-4.44; P = 0.016) were independently associated with hypertension. Conclusions: Hypertension is highly prevalent, underrecognized, and undertreated in alloHSCT survivors and is cross-sectionally associated with subclinical vascular and renal organ damage.
SN  - 2772-963X
ER  -